IBS-C Drugs Market - Global Outlook and Forecast 2022-2028

IBS-C Drugs Market - Global Outlook and Forecast 2022-2028

Report Code: KNJ1156190 | No. of Pages: 124 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: Jan-2022
This report contains market size and forecasts of IBS-C Drugs in global, including the following market information:
Global IBS-C Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global IBS-C Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five IBS-C Drugs companies in 2021 (%)
The global IBS-C Drugs market was valued at  million in 2021 and is projected to reach US$  million by 2028, at a CAGR of  % during the forecast period.
The U.S. Market is Estimated at $  Million in 2021, While China is Forecast to Reach $  Million by 2028.
Linaclotide Segment to Reach $  Million by 2028, with a % CAGR in next six years.
The global key manufacturers of IBS-C Drugs include Catalent Pharmaceuticals Solutions, Nestle, Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Novartis Pharma Ag, Astellas Pharmaceuticals, Ardelyx, Inc and Synthetic Biologics, Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the IBS-C Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global IBS-C Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global IBS-C Drugs Market Segment Percentages, by Type, 2021 (%)
    Linaclotide
    Lubiprostone
    Osmotic Laxatives
    Stimulant Laxatives
    Others
Global IBS-C Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global IBS-C Drugs Market Segment Percentages, by Application, 2021 (%)
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies
Global IBS-C Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global IBS-C Drugs Market Segment Percentages, By Region and Country, 2021 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies IBS-C Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies IBS-C Drugs revenues share in global market, 2021 (%)
Key companies IBS-C Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies IBS-C Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Catalent Pharmaceuticals Solutions
    Nestle
    Abbott Laboratories
    Synergy Pharmaceuticals
    Sucampo Pharmaceuticals
    Novartis Pharma Ag
    Astellas Pharmaceuticals
    Ardelyx, Inc
    Synthetic Biologics, Inc
    Teva Pharmaceutical Industries
    Bama-Geve, SLU
    Ferring BV
    Ironwood Pharmaceuticals, Inc
    Salix Pharmaceuticals Ltd
    Norgine B.V
    Prometheus Laboratories Inc
    Actavis Nordic A/S
    Albireo Pharma Inc
    Yuhan Corp
    Astrazeneca Plc
    The Menarini Group
    Ono Pharmaceutical Co., Ltd
1 Introduction to Research & Analysis Reports
    1.1 IBS-C Drugs Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global IBS-C Drugs Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global IBS-C Drugs Overall Market Size
    2.1 Global IBS-C Drugs Market Size: 2021 VS 2028
    2.2 Global IBS-C Drugs Revenue, Prospects & Forecasts: 2017-2028
    2.3 Global IBS-C Drugs Sales: 2017-2028
3 Company Landscape
    3.1 Top IBS-C Drugs Players in Global Market
    3.2 Top Global IBS-C Drugs Companies Ranked by Revenue
    3.3 Global IBS-C Drugs Revenue by Companies
    3.4 Global IBS-C Drugs Sales by Companies
    3.5 Global IBS-C Drugs Price by Manufacturer (2017-2022)
    3.6 Top 3 and Top 5 IBS-C Drugs Companies in Global Market, by Revenue in 2021
    3.7 Global Manufacturers IBS-C Drugs Product Type
    3.8 Tier 1, Tier 2 and Tier 3 IBS-C Drugs Players in Global Market
        3.8.1 List of Global Tier 1 IBS-C Drugs Companies
        3.8.2 List of Global Tier 2 and Tier 3 IBS-C Drugs Companies
4 Sights by Product
    4.1 Overview
        4.1.1 By Type - Global IBS-C Drugs Market Size Markets, 2021 & 2028
        4.1.2 Linaclotide
        4.1.3 Lubiprostone
        4.1.4 Osmotic Laxatives
        4.1.5 Stimulant Laxatives
        4.1.6 Others
    4.2 By Type - Global IBS-C Drugs Revenue & Forecasts
        4.2.1 By Type - Global IBS-C Drugs Revenue, 2017-2022
        4.2.2 By Type - Global IBS-C Drugs Revenue, 2023-2028
        4.2.3 By Type - Global IBS-C Drugs Revenue Market Share, 2017-2028
    4.3 By Type - Global IBS-C Drugs Sales & Forecasts
        4.3.1 By Type - Global IBS-C Drugs Sales, 2017-2022
        4.3.2 By Type - Global IBS-C Drugs Sales, 2023-2028
        4.3.3 By Type - Global IBS-C Drugs Sales Market Share, 2017-2028
    4.4 By Type - Global IBS-C Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
    5.1 Overview
        5.1.1 By Application - Global IBS-C Drugs Market Size, 2021 & 2028
        5.1.2 Hospital Pharmacies
        5.1.3 Retail Pharmacies
        5.1.4 Online Pharmacies
    5.2 By Application - Global IBS-C Drugs Revenue & Forecasts
        5.2.1 By Application - Global IBS-C Drugs Revenue, 2017-2022
        5.2.2 By Application - Global IBS-C Drugs Revenue, 2023-2028
        5.2.3 By Application - Global IBS-C Drugs Revenue Market Share, 2017-2028
    5.3 By Application - Global IBS-C Drugs Sales & Forecasts
        5.3.1 By Application - Global IBS-C Drugs Sales, 2017-2022
        5.3.2 By Application - Global IBS-C Drugs Sales, 2023-2028
        5.3.3 By Application - Global IBS-C Drugs Sales Market Share, 2017-2028
    5.4 By Application - Global IBS-C Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
    6.1 By Region - Global IBS-C Drugs Market Size, 2021 & 2028
    6.2 By Region - Global IBS-C Drugs Revenue & Forecasts
        6.2.1 By Region - Global IBS-C Drugs Revenue, 2017-2022
        6.2.2 By Region - Global IBS-C Drugs Revenue, 2023-2028
        6.2.3 By Region - Global IBS-C Drugs Revenue Market Share, 2017-2028
    6.3 By Region - Global IBS-C Drugs Sales & Forecasts
        6.3.1 By Region - Global IBS-C Drugs Sales, 2017-2022
        6.3.2 By Region - Global IBS-C Drugs Sales, 2023-2028
        6.3.3 By Region - Global IBS-C Drugs Sales Market Share, 2017-2028
    6.4 North America
        6.4.1 By Country - North America IBS-C Drugs Revenue, 2017-2028
        6.4.2 By Country - North America IBS-C Drugs Sales, 2017-2028
        6.4.3 US IBS-C Drugs Market Size, 2017-2028
        6.4.4 Canada IBS-C Drugs Market Size, 2017-2028
        6.4.5 Mexico IBS-C Drugs Market Size, 2017-2028
    6.5 Europe
        6.5.1 By Country - Europe IBS-C Drugs Revenue, 2017-2028
        6.5.2 By Country - Europe IBS-C Drugs Sales, 2017-2028
        6.5.3 Germany IBS-C Drugs Market Size, 2017-2028
        6.5.4 France IBS-C Drugs Market Size, 2017-2028
        6.5.5 U.K. IBS-C Drugs Market Size, 2017-2028
        6.5.6 Italy IBS-C Drugs Market Size, 2017-2028
        6.5.7 Russia IBS-C Drugs Market Size, 2017-2028
        6.5.8 Nordic Countries IBS-C Drugs Market Size, 2017-2028
        6.5.9 Benelux IBS-C Drugs Market Size, 2017-2028
    6.6 Asia
        6.6.1 By Region - Asia IBS-C Drugs Revenue, 2017-2028
        6.6.2 By Region - Asia IBS-C Drugs Sales, 2017-2028
        6.6.3 China IBS-C Drugs Market Size, 2017-2028
        6.6.4 Japan IBS-C Drugs Market Size, 2017-2028
        6.6.5 South Korea IBS-C Drugs Market Size, 2017-2028
        6.6.6 Southeast Asia IBS-C Drugs Market Size, 2017-2028
        6.6.7 India IBS-C Drugs Market Size, 2017-2028
    6.7 South America
        6.7.1 By Country - South America IBS-C Drugs Revenue, 2017-2028
        6.7.2 By Country - South America IBS-C Drugs Sales, 2017-2028
        6.7.3 Brazil IBS-C Drugs Market Size, 2017-2028
        6.7.4 Argentina IBS-C Drugs Market Size, 2017-2028
    6.8 Middle East & Africa
        6.8.1 By Country - Middle East & Africa IBS-C Drugs Revenue, 2017-2028
        6.8.2 By Country - Middle East & Africa IBS-C Drugs Sales, 2017-2028
        6.8.3 Turkey IBS-C Drugs Market Size, 2017-2028
        6.8.4 Israel IBS-C Drugs Market Size, 2017-2028
        6.8.5 Saudi Arabia IBS-C Drugs Market Size, 2017-2028
        6.8.6 UAE IBS-C Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
    7.1 Catalent Pharmaceuticals Solutions
        7.1.1 Catalent Pharmaceuticals Solutions Corporate Summary
        7.1.2 Catalent Pharmaceuticals Solutions Business Overview
        7.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Major Product Offerings
        7.1.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.1.5 Catalent Pharmaceuticals Solutions Key News
    7.2 Nestle
        7.2.1 Nestle Corporate Summary
        7.2.2 Nestle Business Overview
        7.2.3 Nestle IBS-C Drugs Major Product Offerings
        7.2.4 Nestle IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.2.5 Nestle Key News
    7.3 Abbott Laboratories
        7.3.1 Abbott Laboratories Corporate Summary
        7.3.2 Abbott Laboratories Business Overview
        7.3.3 Abbott Laboratories IBS-C Drugs Major Product Offerings
        7.3.4 Abbott Laboratories IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.3.5 Abbott Laboratories Key News
    7.4 Synergy Pharmaceuticals
        7.4.1 Synergy Pharmaceuticals Corporate Summary
        7.4.2 Synergy Pharmaceuticals Business Overview
        7.4.3 Synergy Pharmaceuticals IBS-C Drugs Major Product Offerings
        7.4.4 Synergy Pharmaceuticals IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.4.5 Synergy Pharmaceuticals Key News
    7.5 Sucampo Pharmaceuticals
        7.5.1 Sucampo Pharmaceuticals Corporate Summary
        7.5.2 Sucampo Pharmaceuticals Business Overview
        7.5.3 Sucampo Pharmaceuticals IBS-C Drugs Major Product Offerings
        7.5.4 Sucampo Pharmaceuticals IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.5.5 Sucampo Pharmaceuticals Key News
    7.6 Novartis Pharma Ag
        7.6.1 Novartis Pharma Ag Corporate Summary
        7.6.2 Novartis Pharma Ag Business Overview
        7.6.3 Novartis Pharma Ag IBS-C Drugs Major Product Offerings
        7.6.4 Novartis Pharma Ag IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.6.5 Novartis Pharma Ag Key News
    7.7 Astellas Pharmaceuticals
        7.7.1 Astellas Pharmaceuticals Corporate Summary
        7.7.2 Astellas Pharmaceuticals Business Overview
        7.7.3 Astellas Pharmaceuticals IBS-C Drugs Major Product Offerings
        7.7.4 Astellas Pharmaceuticals IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.7.5 Astellas Pharmaceuticals Key News
    7.8 Ardelyx, Inc
        7.8.1 Ardelyx, Inc Corporate Summary
        7.8.2 Ardelyx, Inc Business Overview
        7.8.3 Ardelyx, Inc IBS-C Drugs Major Product Offerings
        7.8.4 Ardelyx, Inc IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.8.5 Ardelyx, Inc Key News
    7.9 Synthetic Biologics, Inc
        7.9.1 Synthetic Biologics, Inc Corporate Summary
        7.9.2 Synthetic Biologics, Inc Business Overview
        7.9.3 Synthetic Biologics, Inc IBS-C Drugs Major Product Offerings
        7.9.4 Synthetic Biologics, Inc IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.9.5 Synthetic Biologics, Inc Key News
    7.10 Teva Pharmaceutical Industries
        7.10.1 Teva Pharmaceutical Industries Corporate Summary
        7.10.2 Teva Pharmaceutical Industries Business Overview
        7.10.3 Teva Pharmaceutical Industries IBS-C Drugs Major Product Offerings
        7.10.4 Teva Pharmaceutical Industries IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.10.5 Teva Pharmaceutical Industries Key News
    7.11 Bama-Geve, SLU
        7.11.1 Bama-Geve, SLU Corporate Summary
        7.11.2 Bama-Geve, SLU IBS-C Drugs Business Overview
        7.11.3 Bama-Geve, SLU IBS-C Drugs Major Product Offerings
        7.11.4 Bama-Geve, SLU IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.11.5 Bama-Geve, SLU Key News
    7.12 Ferring BV
        7.12.1 Ferring BV Corporate Summary
        7.12.2 Ferring BV IBS-C Drugs Business Overview
        7.12.3 Ferring BV IBS-C Drugs Major Product Offerings
        7.12.4 Ferring BV IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.12.5 Ferring BV Key News
    7.13 Ironwood Pharmaceuticals, Inc
        7.13.1 Ironwood Pharmaceuticals, Inc Corporate Summary
        7.13.2 Ironwood Pharmaceuticals, Inc IBS-C Drugs Business Overview
        7.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Major Product Offerings
        7.13.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.13.5 Ironwood Pharmaceuticals, Inc Key News
    7.14 Salix Pharmaceuticals Ltd
        7.14.1 Salix Pharmaceuticals Ltd Corporate Summary
        7.14.2 Salix Pharmaceuticals Ltd Business Overview
        7.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Major Product Offerings
        7.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.14.5 Salix Pharmaceuticals Ltd Key News
    7.15 Norgine B.V
        7.15.1 Norgine B.V Corporate Summary
        7.15.2 Norgine B.V Business Overview
        7.15.3 Norgine B.V IBS-C Drugs Major Product Offerings
        7.15.4 Norgine B.V IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.15.5 Norgine B.V Key News
    7.16 Prometheus Laboratories Inc
        7.16.1 Prometheus Laboratories Inc Corporate Summary
        7.16.2 Prometheus Laboratories Inc Business Overview
        7.16.3 Prometheus Laboratories Inc IBS-C Drugs Major Product Offerings
        7.16.4 Prometheus Laboratories Inc IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.16.5 Prometheus Laboratories Inc Key News
    7.17 Actavis Nordic A/S
        7.17.1 Actavis Nordic A/S Corporate Summary
        7.17.2 Actavis Nordic A/S Business Overview
        7.17.3 Actavis Nordic A/S IBS-C Drugs Major Product Offerings
        7.17.4 Actavis Nordic A/S IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.17.5 Actavis Nordic A/S Key News
    7.18 Albireo Pharma Inc
        7.18.1 Albireo Pharma Inc Corporate Summary
        7.18.2 Albireo Pharma Inc Business Overview
        7.18.3 Albireo Pharma Inc IBS-C Drugs Major Product Offerings
        7.18.4 Albireo Pharma Inc IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.18.5 Albireo Pharma Inc Key News
    7.19 Yuhan Corp
        7.19.1 Yuhan Corp Corporate Summary
        7.19.2 Yuhan Corp Business Overview
        7.19.3 Yuhan Corp IBS-C Drugs Major Product Offerings
        7.19.4 Yuhan Corp IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.19.5 Yuhan Corp Key News
    7.20 Astrazeneca Plc
        7.20.1 Astrazeneca Plc Corporate Summary
        7.20.2 Astrazeneca Plc Business Overview
        7.20.3 Astrazeneca Plc IBS-C Drugs Major Product Offerings
        7.20.4 Astrazeneca Plc IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.20.5 Astrazeneca Plc Key News
    7.21 The Menarini Group
        7.21.1 The Menarini Group Corporate Summary
        7.21.2 The Menarini Group Business Overview
        7.21.3 The Menarini Group IBS-C Drugs Major Product Offerings
        7.21.4 The Menarini Group IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.21.5 The Menarini Group Key News
    7.22 Ono Pharmaceutical Co., Ltd
        7.22.1 Ono Pharmaceutical Co., Ltd Corporate Summary
        7.22.2 Ono Pharmaceutical Co., Ltd Business Overview
        7.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Major Product Offerings
        7.22.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales and Revenue in Global (2017-2022)
        7.22.5 Ono Pharmaceutical Co., Ltd Key News
8 Global IBS-C Drugs Production Capacity, Analysis
    8.1 Global IBS-C Drugs Production Capacity, 2017-2028
    8.2 IBS-C Drugs Production Capacity of Key Manufacturers in Global Market
    8.3 Global IBS-C Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
    9.1 Market Opportunities & Trends
    9.2 Market Drivers
    9.3 Market Restraints
10 IBS-C Drugs Supply Chain Analysis
    10.1 IBS-C Drugs Industry Value Chain
    10.2 IBS-C Drugs Upstream Market
    10.3 IBS-C Drugs Downstream and Clients
    10.4 Marketing Channels Analysis
        10.4.1 Marketing Channels
        10.4.2 IBS-C Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
    12.1 Note
    12.2 Examples of Clients
    12.3 Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com